About Us
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®.
Contacts
-
Ulf Hannelius
CEO
Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
+46 8 661 63 68
https://www.diamyd.com
press@diamyd.com